{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:24:14Z","timestamp":1793049854317,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00198-018-4688-1","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T23:58:05Z","timestamp":1536105485000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency"],"prefix":"10.1007","volume":"30","author":[{"given":"D.","family":"Miyaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Y.","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"4688_CR1","doi-asserted-by":"publisher","first-page":"e3427","DOI":"10.1136\/bmj.e3427","volume":"344","author":"J Hippisley-Cox","year":"2012","unstructured":"Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427","journal-title":"BMJ"},{"issue":"12","key":"4688_CR2","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ndt\/gfw354","volume":"31","author":"A Gasparini","year":"2016","unstructured":"Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR, Runesson B, Barany P, \u00c4rnl\u00f6v J, Jernberg T, Wettermark B, Elinder CG, Carrero JJ (2016) Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant 31(12):2086\u20132094","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"4688_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"7","key":"4688_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"4688_CR5","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829\u20131835","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4688_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol 41(2):129\u2013137","journal-title":"Am J Nephrol"},{"issue":"11","key":"4688_CR7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"AL Huynh","year":"2016","unstructured":"Huynh AL, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf 25(11):1274\u20131278","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"4688_CR8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","volume":"36","author":"N Okada","year":"2013","unstructured":"Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36(10):1622\u20131626","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"4688_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1060028014539919","volume":"48","author":"H Ikesue","year":"2014","unstructured":"Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, Uchida M, Egashira N, Miyamoto T, Baba E, Akashi K, Takayama K, Nakanishi Y, Tokunaga E, Okamoto T, Maehara Y, Yokomizo A, Naito S, Kubo M, Tanaka M, Masuda S (2014) Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving Denosumab for the treatment of bone metastases from Cancer. Ann Pharmacother 48(9):1159\u20131165","journal-title":"Ann Pharmacother"},{"issue":"6","key":"4688_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","volume":"50","author":"E Imai","year":"2007","unstructured":"Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis 50(6):927\u2013937","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4688_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1359\/jbmr.2001.16.4.605","volume":"16","author":"P Gao","year":"2001","unstructured":"Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16(4):605\u2013614","journal-title":"J Bone Miner Res"},{"issue":"3","key":"4688_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A Miyauchi","year":"2010","unstructured":"Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47(3):493\u2013502","journal-title":"Bone"},{"issue":"3","key":"4688_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00774-007-0826-0","volume":"26","author":"Y Nishizawa","year":"2008","unstructured":"Nishizawa Y, Inaba M, Ishii M, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, Kurasawa K, Mochizuki Y (2008) Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26(3):265\u2013270","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"4688_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-004-1712-4","volume":"16","author":"S Okuno","year":"2005","unstructured":"Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16(5):501\u2013509","journal-title":"Osteoporos Int"},{"issue":"4","key":"4688_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","volume":"82","author":"K Shidara","year":"2008","unstructured":"Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82(4):278\u2013287","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"4688_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the study of osteoporotic fractures research group. J Bone Miner Res 11(7):984\u2013996","journal-title":"J Bone Miner Res"},{"issue":"7","key":"4688_CR17","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27(7):1471\u20131479","journal-title":"J Bone Miner Res"},{"issue":"3","key":"4688_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Shiraki M (2012) Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23(3):1131\u20131140","journal-title":"Osteoporos Int"},{"issue":"1","key":"4688_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","volume":"66","author":"R Hiramatsu","year":"2015","unstructured":"Hiramatsu R, Ubara Y, Sawa N, Hoshino J, Hasegawa E, Kawada M, Imafuku A, Sumida K, Mise K, Hayami N, Suwabe T, Takaichi K (2015) Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial. Am J Kidney Dis 66(1):175\u2013177","journal-title":"Am J Kidney Dis"},{"key":"4688_CR20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831\u20131840","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"4688_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00198-016-3755-8","volume":"28","author":"J Chen","year":"2017","unstructured":"Chen J, Smerdely P (2017) Hypocalcaemia after denosumab in older people following fracture. Osteoporos Int 28(2):517\u2013522","journal-title":"Osteoporos Int"},{"issue":"13","key":"4688_CR22","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, Stopeck A, van Poznak C, Dami\u00e3o R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51(13):1812\u20131821","journal-title":"Eur J Cancer"},{"issue":"8","key":"4688_CR23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/2211-5463.12258","volume":"7","author":"K Watanabe","year":"2017","unstructured":"Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G, Nagase H, Miyaura C, Inada M (2017) Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio 7(8):1178\u20131185","journal-title":"FEBS Open Bio"},{"issue":"2","key":"4688_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5414\/CNP64098","volume":"64","author":"M Cochran","year":"2005","unstructured":"Cochran M, Coates PT, Morris HA (2005) The effect of calcitriol on fasting urine calcium loss and renal tubular reabsorption of calcium in patients with mild renal failure--actions of a permissive hormone. Clin Nephrol 64(2):98\u2013102","journal-title":"Clin Nephrol"},{"issue":"2","key":"4688_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5414\/CN108223","volume":"82","author":"KR Phelps","year":"2014","unstructured":"Phelps KR, Stote KS, Mason D (2014) Tubular calcium reabsorption and other aspects of calcium homeostasis in primary and secondary hyperparathyroidism. Clin Nephrol 82(2):83\u201391","journal-title":"Clin Nephrol"},{"issue":"5","key":"4688_CR26","first-page":"566","volume":"19","author":"M Cozzolino","year":"2006","unstructured":"Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G (2006) Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 19(5):566\u2013577","journal-title":"J Nephrol"},{"issue":"5","key":"4688_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000338299","volume":"35","author":"L Viaene","year":"2012","unstructured":"Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P (2012) Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease. Am J Nephrol 35(5):434\u2013441","journal-title":"Am J Nephrol"},{"issue":"6","key":"4688_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2215\/CJN.08610812","volume":"8","author":"LA Armas","year":"2013","unstructured":"Armas LA, Zena M, Lund R, Heaney RP (2013) Calcium absorption response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 8(6):1003\u20131008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4688_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1152\/physrev.00003.2004","volume":"85","author":"JG Hoenderop","year":"2005","unstructured":"Hoenderop JG, Nilius B, Bindels RJ (2005) Calcium absorption across epithelia. Physiol Rev 85(1):373\u2013422","journal-title":"Physiol Rev"},{"issue":"5","key":"4688_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1507\/endocrj.EJ16-0003","volume":"63","author":"Y Kinoshita","year":"2016","unstructured":"Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S (2016) High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocr J 63(5):479\u2013484","journal-title":"Endocr J"},{"issue":"4","key":"4688_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/0002-9343(88)90100-3","volume":"84","author":"AR Brasier","year":"1988","unstructured":"Brasier AR, Nussbaum SR (1988) Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84(4):654\u2013660","journal-title":"Am J Med"},{"issue":"5","key":"4688_CR32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00520-016-3543-1","volume":"25","author":"JJ Body","year":"2017","unstructured":"Body JJ, Niepel D, Tonini G (2017) Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer 25(5):1639\u20131649","journal-title":"Support Care Cancer"},{"issue":"10","key":"4688_CR33","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtim\u00e4ki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Siev\u00e4nen H, Vuori I, V\u00e4\u00e4n\u00e4nen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20(10):1804\u20131812","journal-title":"J Bone Miner Res"},{"issue":"5","key":"4688_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1532-5415.2004.52218.x","volume":"52","author":"H Hansdottir","year":"2004","unstructured":"Hansdottir H, Franzson L, Prestwood K, Sigurdsson G (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52(5):779\u2013783","journal-title":"J Am Geriatr Soc"},{"issue":"9886","key":"4688_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50\u201356","journal-title":"Lancet"},{"issue":"3","key":"4688_CR36","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26(3):530\u2013537","journal-title":"J Bone Miner Res"},{"key":"4688_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","volume":"95","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ (2017) Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone 95:20\u201325","journal-title":"Bone"},{"issue":"4","key":"4688_CR38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10067-016-3447-y","volume":"36","author":"BC Cheng","year":"2017","unstructured":"Cheng BC, Chen YC (2017) Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density. Clin Rheumatol 36(4):929\u2013932","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4688_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/13102818.2014.967827","volume":"28","author":"T Petranova","year":"2014","unstructured":"Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28(6):1127\u20131137","journal-title":"Biotechnol Biotechnol Equip"},{"issue":"30","key":"4688_CR40","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875\u20134882","journal-title":"J Clin Oncol"},{"issue":"9992","key":"4688_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433\u2013443","journal-title":"Lancet"},{"issue":"10","key":"4688_CR42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P (2015) Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism 64(10):1291\u20131297","journal-title":"Metabolism"},{"issue":"5","key":"4688_CR43","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00198-017-3923-5","volume":"28","author":"M Kamimura","year":"2017","unstructured":"Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients: response to comments. Osteoporos Int 28(5):1757\u20131758","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4688-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4688-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4688-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T16:10:34Z","timestamp":1593274234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4688-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4688"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4688-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MI received grant support and lecture fees from Daiichi Sankyo Co., Limited. YI, KM, EM, and MI received lecture fees from Daiichi Sankyo Co., Limited. DM, MO, NH, YN, and SY have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All participants provided written informed consent. The study protocol was approved by the institutional ethics committee of Osaka City University Graduate School of Medicine. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}]}}